Icenticaftor, Novel Therapy for COPD: This Glass Is Half Full

A large phase II clinical trial tested icenticaftor, a cystic fibrosis (CF) transmembrane regulator modulator, in chronic obstructive pulmonary disease (COPD) patients. While it failed to improve airflow at 12 weeks as its primary goal, secondary data showed promise, especially at 24 weeks with certain doses. A responder analysis revealed potential benefits, suggesting that a subset of patients might respond well. The study highlights the need for companion diagnostics to identify potential responders, similar to oncology practices. COPD's heterogeneity makes such approaches crucial in developing novel treatments. Despite the trial's primary failure, icenticaftor holds promise in the COPD treatment landscape.